Review




Structured Review

Sequenom sequenom massarray methylation
Fig. 4. Cd interfered with the DNA <t>methylation</t> of Oct4 and Nanog of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom <t>MassARRAY</t> Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C–K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.
Sequenom Massarray Methylation, supplied by Sequenom, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/analysis+massarray+methylation+sequenom/pm34871855-191-17-17
Average 86 stars, based on 1 article reviews
sequenom massarray methylation - by Bioz Stars, 2026-09
86/100 stars

Images

1) Product Images from "Ultra-high field spinal cord MRI in multiple sclerosis: Where are we standing? A literature review."

Article Title: Ultra-high field spinal cord MRI in multiple sclerosis: Where are we standing? A literature review.

Journal: Multiple sclerosis and related disorders

doi: 10.1016/j.msard.2021.103436

Fig. 4. Cd interfered with the DNA methylation of Oct4 and Nanog of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom MassARRAY Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C–K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.
Figure Legend Snippet: Fig. 4. Cd interfered with the DNA methylation of Oct4 and Nanog of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom MassARRAY Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C–K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.

Techniques Used: DNA Methylation Assay, Methylation

Fig. 5. Cd interfered with the DNA methylation of Amhr2 and Sox2 of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom MassARRAY Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C-K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.
Figure Legend Snippet: Fig. 5. Cd interfered with the DNA methylation of Amhr2 and Sox2 of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom MassARRAY Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C-K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.

Techniques Used: DNA Methylation Assay, Methylation

Related Articles

Methylation:

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics
Article Snippet: .. Sequenom MassARRAY methylation analysis was used to detect the HIF-1α−25 promoter methylation level (Figure and Tables and ). ..

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics.
Article Snippet: .. Sequenom MassARRAY methylation analysis was used to detect the HIF-1α−25 promoter methylation level (Figure S1 and Tables 3 and 4). ..

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics.
Article Snippet: .. Alcohol administration enhanced HIF-1α−25 promoter methylation in rats at weeks 8 and 10 Sequenom MassARRAY methylation analysis was conducted to detect the HIF-1α−25 promoter methylation status in the Control and Alcohol groups at weeks 6, 8, and 10 (Table 2 and Figure S1). ..

Article Title: SNCA inhibits breast cancer progression through TP53AIP1–p53-mediated mitochondrial apoptosis and suppression of cancer stemness
Article Snippet: .. 320 321 Sequenom mass ARRAY methylation analysis 322 Genomic DNA extracted from BC tissues was treated with sodium bisulfite using the 323 BisulFlash DNA Modification Kit (EpiGentek, Farmingdale, New York, USA) 324 following the manufacturer's guidelines. .. The methylation status of the SNCA 325 promoter region was evaluated using the Seuenom Mass ARRAY platform provided 326 by BioMiao Biological Technology.

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics.
Article Snippet: .. Methylation-Specific PCR, Sequenom MassARRAY methylation, ELISA, Western blot, and correlation analysis of 16S rRNA sequencing and metabolomics were performed. ..

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics.
Article Snippet: .. Measurement of methylation level was conducted by quantitative methylation analysis (Sequenom). ..

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics
Article Snippet: Note: AP: Acute Pancreatitis; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; GGT: Gamma-Glutamyl Transferase; BUN: Blood Urea Nitrogen; ALP: Alkaline Phosphatase; CREA: Creatinine; HE: Hematoxylin and Eosin; ELISA: Enzyme-Linked Immunosorbent Assay; HIF-1α: Hypoxia-inducible factor 1 alpha; VEGF: Vascular Endothelial Growth Factor .. Sequenom MassARRAY methylation analysis was conducted to detect the HIF-1α−25 promoter methylation status in the Control and Alcohol groups at weeks 6, 8, and 10 (Table and Figure ). ..

Control:

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics.
Article Snippet: .. Alcohol administration enhanced HIF-1α−25 promoter methylation in rats at weeks 8 and 10 Sequenom MassARRAY methylation analysis was conducted to detect the HIF-1α−25 promoter methylation status in the Control and Alcohol groups at weeks 6, 8, and 10 (Table 2 and Figure S1). ..

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics
Article Snippet: Note: AP: Acute Pancreatitis; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; GGT: Gamma-Glutamyl Transferase; BUN: Blood Urea Nitrogen; ALP: Alkaline Phosphatase; CREA: Creatinine; HE: Hematoxylin and Eosin; ELISA: Enzyme-Linked Immunosorbent Assay; HIF-1α: Hypoxia-inducible factor 1 alpha; VEGF: Vascular Endothelial Growth Factor .. Sequenom MassARRAY methylation analysis was conducted to detect the HIF-1α−25 promoter methylation status in the Control and Alcohol groups at weeks 6, 8, and 10 (Table and Figure ). ..

Modification:

Article Title: SNCA inhibits breast cancer progression through TP53AIP1–p53-mediated mitochondrial apoptosis and suppression of cancer stemness
Article Snippet: .. 320 321 Sequenom mass ARRAY methylation analysis 322 Genomic DNA extracted from BC tissues was treated with sodium bisulfite using the 323 BisulFlash DNA Modification Kit (EpiGentek, Farmingdale, New York, USA) 324 following the manufacturer's guidelines. .. The methylation status of the SNCA 325 promoter region was evaluated using the Seuenom Mass ARRAY platform provided 326 by BioMiao Biological Technology.

Polymerase Chain Reaction:

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics.
Article Snippet: .. Methylation-Specific PCR, Sequenom MassARRAY methylation, ELISA, Western blot, and correlation analysis of 16S rRNA sequencing and metabolomics were performed. ..

Enzyme-linked Immunosorbent Assay:

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics.
Article Snippet: .. Methylation-Specific PCR, Sequenom MassARRAY methylation, ELISA, Western blot, and correlation analysis of 16S rRNA sequencing and metabolomics were performed. ..

Western Blot:

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics.
Article Snippet: .. Methylation-Specific PCR, Sequenom MassARRAY methylation, ELISA, Western blot, and correlation analysis of 16S rRNA sequencing and metabolomics were performed. ..

Sequencing:

Article Title: In-depth investigation of the mechanism in rats with alcoholic acute pancreatitis via DNA methylation, intestinal flora, and fecal metabolomics.
Article Snippet: .. Methylation-Specific PCR, Sequenom MassARRAY methylation, ELISA, Western blot, and correlation analysis of 16S rRNA sequencing and metabolomics were performed. ..



Similar Products

90
Sequenom massarray sequenom detection
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray Sequenom Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc09085879-184-7-8
Average 90 stars, based on 1 article reviews
massarray sequenom detection - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sequenom snps detected by sequenom massarray rs1000 platform
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Snps Detected By Sequenom Massarray Rs1000 Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/massarray+rs1000/pm33127268-102-12-16
Average 90 stars, based on 1 article reviews
snps detected by sequenom massarray rs1000 platform - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sequenom mass spectrometry-based detection (sequenom massarray platform)
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Mass Spectrometry Based Detection (Sequenom Massarray Platform), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc06107190-119-25-28
Average 90 stars, based on 1 article reviews
mass spectrometry-based detection (sequenom massarray platform) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sequenom detection limitation of sequenom massarray
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Detection Limitation Of Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc05863829-107-32-31
Average 90 stars, based on 1 article reviews
detection limitation of sequenom massarray - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sequenom mass spectrometric detection (sequenom massarray)
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Mass Spectrometric Detection (Sequenom Massarray), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pm26003169-313-9-12
Average 90 stars, based on 1 article reviews
mass spectrometric detection (sequenom massarray) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sequenom mass spectrometric detection sequenom massarray
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Mass Spectrometric Detection Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc04258414-60-7-10
Average 90 stars, based on 1 article reviews
mass spectrometric detection sequenom massarray - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sequenom single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Single Nucleotide Extension Reaction With Allele Detection By Mass Spectrometry Sequenom Massarray System, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/modified+single+nucleotide+extension+reaction+with+allele+detection+by+mass+spectrometry+sequenom+massarray+system/pmc06869631-79-12-14
Average 90 stars, based on 1 article reviews
single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Journal: Cell Death & Disease

Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

doi: 10.1038/s41419-022-04895-6

Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Article Snippet: And meanwhile, in clinical samples, we used MassArray Sequenom detection to further verify the DNA methylation changes of ZNF334 promoter in cancerous tissues and adjacent tissues.

Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing